Rahul Ahuja
Veterans Health Administration
11 Papers
2 Citations
Rahul Ahuja is an academic researcher from Veterans Health Administration. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 3, co-authored 4 publications. Previous affiliations of Rahul Ahuja include Genentech & San Francisco VA Medical Center.
Chat about Author
Papers
An Allosteric Anti-tryptase Antibody for the Treatment of Mast Cell-Mediated Severe Asthma
Henry R. Maun,Janet Jackman,David F. Choy,Kelly M. Loyet,Tracy Staton,Guiquan Jia,Amy Dressen,Jason A. Hackney,Meire Bremer,Benjamin T. Walters,Rajesh Vij,Xiaocheng Chen,Neil N. Trivedi,Neil N. Trivedi,Ashley Morando,Michael T. Lipari,Yvonne Franke,Xiumin Wu,Juan Zhang,John Liu,Ping Wu,Diana Chang,Luz D. Orozco,Erin H. Christensen,Manda Wong,Racquel Corpuz,Julie Q. Hang,Jeff Lutman,Siddharth Sukumaran,Yan Wu,Savita Ubhayakar,Xiaorong Liang,Lawrence B. Schwartz,Magda Babina,Prescott G. Woodruff,John V. Fahy,Rahul Ahuja,Rahul Ahuja,George H. Caughey,George H. Caughey,Aija Kusi,Mark S. Dennis,Charles Eigenbrot,Daniel Kirchhofer,Cary D. Austin,Lawren C. Wu,James T. Koerber,Wyne P. Lee,Brian L. Yaspan,Kathila R. Alatsis,Joseph R. Arron,Robert A. Lazarus,Tangsheng Yi +52 more
TL;DR: A noncompetitive inhibitory antibody against human β-tryptase is generated that potently blocks tryptase enzymatic activity in a humanized mouse model, reducing IgE-mediated systemic anaphylaxis, and inhibits airwaytryptase in Ascaris-sensitized cynomolgus monkeys with favorable pharmacokinetics.
94
Donor-Reactive Regulatory T Cell Frequency Increases During Acute Cellular Rejection of Lung Allografts.
John R. Greenland,Charissa M. Wong,Rahul Ahuja,Angelia S. Wang,Chiyo Uchida,Jeffrey A. Golden,Steven R. Hays,Lorriana E. Leard,Raja Rajalingam,Jonathan P. Singer,Jasleen Kukreja,Paul J. Wolters,George H. Caughey,Qizhi Tang +13 more
TL;DR: Contrary to prediction, overall proportions of donor-reactive Treg cells are similar before and after transplantation and increase during grade A2 rejection, which suggests how A1 rejection can be self-limiting.
RBD decorated PLA nanoparticle admixture with aluminum hydroxide elicit robust and long lasting immune response against SARS-CoV-2
Jairam Meena,Priyank Singhvi,Sudeepa Srichandan,Jyotsna Dandotiya,Juhi Verma,MamtaSingh,Rahul Ahuja,N. R. Panwar,Tabiya Qayoom Wani,Ritika Khatri,Gazala Siddiqui,Anuradha Gupta,Sweety Samal,Amulya Kumar Panda +13 more
TL;DR: In this paper , a nanoparticle vaccine with multivalent display of receptor binding domain (RBD) was developed against global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) expressed in E. coli.
10
Immunogenicity Evaluation of Thermostable Microparticles Entrapping Receptor Binding Domain of SARS-CoV-2 by Single Point Administration
TL;DR: In this article , the authors examined the immunogenicity of RBD delivered by biodegradable polymer particles from single dose administration and found that the polymer microparticles showed better temperature stability and could be stored at 37 degrees for one month without any considerable loss of immunogenity.
2
Enhanced expression and solubility of main protease (Mpro) of SARS-CoV-2 from E. coli.
Tanmay Majumdar,Rahul Ahuja,G. Kumari,Atul Kumar Roy,Amit Kumar,Anupamjeet Kaur,Santosh Kumar +6 more
TL;DR: In this article , the main protease (Mpro) of SARS-CoV-2 was achieved using two E. coli hosts, namely BL21-DE3 and BL21 -DE3-RIL.
2